J&J touts their head-to-head win against Sanofi on MS, steering another S1P drug to the FDA
J&J investigators say they racked up a positive set of numbers for their Phase III pivotal study of the S1P1 drug ponesimod in a head …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
